Citigroup analyst Amit Hazan maintained a Buy rating on Becton Dickinson (BDX) today and set a price target of $279. The company’s shares closed yesterday at $236.22.
According to TipRanks.com, Hazan is a 4-star analyst with an average return of 10.3% and a 56.8% success rate. Hazan covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Varian Medical Systems, and Edwards Lifesciences.
Becton Dickinson has an analyst consensus of Strong Buy, with a price target consensus of $272.75, which is a 15.5% upside from current levels. In a report issued on November 6, Piper Jaffray also maintained a Buy rating on the stock with a $250 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $265.87 and a one-year low of $209.91. Currently, Becton Dickinson has an average volume of 1.02M.
Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
